A Phase 4 interventional study of Simvastatin combined with Amlodipine besylate and Simvastatin combined with Spironolactone and Amlodipine besylate. in Primary Aldosteronism, Statin and Mineralocorticoid Receptor Antagonist, sponsored by Third Military Medical University. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Third Military Medical University · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Hyperaldosteronism by Third Military Medical University — 3 open to participants now, 4 under way, none of them phase 3. Hyperaldosteronism · Third Military Medical University.
Among the 10 studies in Hyperaldosteronism by Third Military Medical University, this one is the only one that started in 2024, is the only one in phase 4, and was the 8th registered.
201 studies on the registry are indexed under Hyperaldosteronism; 91 are open to participants now.
Browse Hyperaldosteronism studies →3 of the 10 studies in Hyperaldosteronism by Third Military Medical University are open now, in 1 country. Recruiting first, the newest first:
Third Military Medical University · Sites in China
Ages 18–70
Third Military Medical University · Sites in China
Ages 30–65
Third Military Medical University · Sites in China
Ages 30–60
By country, each count listing its studies:
Of the 68 Hyperaldosteronism studies recruiting now, 22 (32%) set no upper age limit and 30 (44%) stop at 75 or younger; 6 take children under 18; 14 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 180 is above the median of 63 across 94 interventional studies indexed under Hyperaldosteronism.
Median enrollment 55 across the 6 interventional studies, 103 across the 4 observational. Of the 4 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Third Military Medical University is the lead sponsor of 84 studies on the registry; 17 are open to participants now.
1 of the studies in Hyperaldosteronism by Third Military Medical University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07884955Third Military Medical UniversityComparing Inclisiran Versus Statin for Primary Aldosteronism | 2027-08-01 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies in Hyperaldosteronism by Third Military Medical University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The drug treatment for primary aldosteronism (PA) is limited and difficult to improve long-term cardiovascular outcomes. This study plans to enroll patients with primary aldosteronism and randomly divide into 3 groups: scheme 1: Statin combined with amlodipine besylate, scheme 2: Statin combined with Spironolactone and Amlodipine besylate. scheme 3: Amlodipine besylate combined with Spironolactone , to observe the changes in plasma aldosterone level, 24-hour urinary aldosterone, blood pressure, and long-term cardiovascular risk.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
after 1:1 randomization, 60 patients with primary aldosteronism were treated with Simvastatin combined with Amlodipine besylate for 6 months
Drug: Simvastatin combined with Amlodipine besylate
after 1:1 randomization, 60 patients with primary aldosteronism were treated with Simvastatin combined with Spironolactone and Amlodipine besylate for 6 months
Drug: Simvastatin combined with Spironolactone and Amlodipine besylate.
after 1:1 randomization, 60 patients with primary aldosteronism were treated with Amlodipine besylate combined with Spironolactone for 6 months
Drug: Amlodipine besylate combined Spironolactone
Drug pages: SimvastatinStudies of SimvastatinSimvastatin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · AmlodipineStudies of AmlodipineAmlodipine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
6-month treatment of Simvastatin combined with Amlodipine besylate
6-month treatment of Simvastatin combined with Spironolactone and Amlodipine besylate.
6-month treatment of Amlodipine besylate combined with Spironolactone
changes in plasma aldosterone levels
blood samples are collected at baseline and 6 months after treatment to measure plasma aldosterone levels, and compare between groups and within groups (pg/ml)
Time frame: 6 month
changes in 24-hour urinary aldosterone levels
24 hours urine are collected at baseline and 6 months after treatment to measure 24-hour urinary aldosterone, and compare between groups and within groups(pmol/24h)
Time frame: 6 month
changes in office blood pressure
Record office blood pressure at baseline and at follow-up after medical treatment (mmHg), and compare between groups and within groups
Time frame: 6 month
changes in serum potassium levels
blood samples are collected at baseline and 6 months after treatment to measure serum potassium levels, and compare between groups and within groups (mmol/L)
Time frame: 6 month
changes in serum renin level
blood samples are collected at baseline and 6 months after treatment to measure serum renin levels, and compare between groups and within groups (mU/L)
Time frame: 6 month
changes in plasma cholesterol levels
blood samples are collected at baseline and 6 months after treatment to measure plasma cholesterol levels, and compare between groups and within groups (mmol/L)
Time frame: 6 month
changes in blood glucose
blood samples are collected at baseline and 6 months after treatment to measure blood glucose, and compare between groups and within groups (mmol/L)
Time frame: 6 month
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2024 (actual). Primary completion is estimated for Nov 2026, 26 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 16, 2026: primary completion Dec 2025 → Nov 2026 and completion Sep 2026 → Nov 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Simvastatin · Amlodipine
Third Military Medical University